TYK2/JAK1 Inhibitor PF-06700841 in Patients with Plaque Psoriasis: Phase IIa, Randomized, Double-Blind, Placebo-Controlled Trial
Seth Forman, David M. Pariser, Yves Poulin, Michael S. Vincent, Steven A. Gilbert, Elizabeth Kieras, Ruolun Qiu, Dahong Yu, Jocelyne Papacharalambous, Christopher Tehlirian, Elena Peeva
Topics & Concepts
PlaceboDouble blindMedicinePsoriasisPlaque psoriasisDermatologyInternal medicineRandomized controlled trialPharmacologyPathologyAlternative medicineCytokine Signaling Pathways and InteractionsPsoriasis: Treatment and PathogenesisNF-κB Signaling Pathways